Business Context and Reporting Period
Filing identity: The provided Form 10-Q is for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It covers the unaudited quarter ended March 31, 2012 and was filed May 15, 2012.
Zeta was a Delaware development-stage, blank-check and shell company incorporated on November 16, 2007. Its objective was to identify and complete a business combination with an operating company. The filing states that no target had been identified and that management had not held discussions with potential combination candidates.
Financial Highlights
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating loss | $4,241 | $4,266 |
| Interest expense | $1,131 | $888 |
| Net loss | $5,372 | $5,154 |
| Net loss per share | $0.00 loss | $0.00 loss |
| Cash used in operating activities | $5,477 | $2,264 |
| Cash provided by financing activities | $25,000 | $0 |
| Cash and cash equivalents at period-end | $23,743 | $24,634 |
At March 31, 2012, total assets were $24,368, consisting primarily of cash and prepaid expenses. Current liabilities were $97,771, including $85,000 of notes payable to stockholders, $7,455 of accrued interest, $3,816 of accounts payable and $1,500 of accrued expenses. Stockholders’ deficit was $73,403.
During the quarter, stockholders provided $25,000 through unsecured, demand promissory notes bearing 6% interest. No investing activity occurred. Cumulative net loss since inception was $123,403, and cumulative cash used in operating activities was $111,257.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $218, or approximately 4%, from $5,154 to $5,372.
- Operating cash use increased by $3,213, from $2,264 to $5,477.
- Financing provided $25,000 in Q1 2012, compared with no financing proceeds in Q1 2011.
- Period-end cash decreased by $891 year over year, despite the current-quarter stockholder financing.
- Total liabilities increased from $74,751 at December 31, 2011 to $97,771 at March 31, 2012, primarily because stockholder notes increased by $25,000.
- The company continued to generate no revenue and conduct no active operating business.
Outlook, Risks and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected ongoing costs for SEC reporting and acquisition investigation. Management stated that funding would likely need to come from treasury cash, deferred service-provider fees, stockholder or management loans, equity financing, or a reverse-merger transaction.
The filing includes a going-concern uncertainty. The company cannot assure that it can satisfy cash requirements for the next twelve months and depends on related-party funding, future financing, profitable operations, and completion of a suitable business combination. No assurance was provided that additional funding or a target transaction would become available.
The company had no revenues, no material off-balance-sheet arrangements, no material pending legal proceedings and no reported defaults or unregistered equity sales during the quarter. Office space and equipment were provided by an officer and director at no cost under a month-to-month arrangement, which management considered de minimis. Disclosure controls were assessed as effective, with no material changes to internal control over financial reporting.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing is for Zeta Acquisition Corp. III, while the request identifies Kura Oncology, Inc.
- Confirm the company’s shell-company, blank-check status and whether any subsequent business combination occurred.
- Review the $85,000 stockholder note balance, 6% interest rate, demand repayment terms and accrued interest.
- Assess the going-concern disclosure and the company’s ability to obtain additional related-party or equity financing.
- Confirm that no target company had been identified and that the company had generated no revenue since inception.
- Reconcile the quarter-end cash balance of $23,743 with operating cash use of $5,477 and stockholder financing of $25,000.